Buscar
Mostrando ítems 1-10 de 278
Pharmacogenomics in Latin America: Challenges and Opportunities
(Nova Science, 2017)
The incorporation of clinical guidelines of pharmacogenomics in Latin America
(Nova Science, 2017)
In Latin America the Pharmacogenetics and Pharmacogenomics areas are recently emerging
fields and the main focus of the research is to evaluate ethnic differences to apply adapted
guidelines to manage personalized ...
SLC2A4 gene: a promising target for pharmacogenomics of insulin resistance
(Ashley PublicationsLondres, 2013-06)
Cardiovascular pharmacogenomics: Clinical applications in Latin America
(Nova Science Publishers, Inc., 2017)
© 2011 by Nova Science Publishers, Inc. All rights reserved. Cardiovascular diseases (CVDs) are the number one cause of death globally. Most cardiovascular diseases can be prevented by addressing behavioral risk factors ...
Pharmacogenomics of vitamin K antagonists
(SOC MEDICA SANTIAGO, 2020)
Pharmacogenomics in psychiatric practice: Latin America initiatives
(Nova Science, 2017)
Pharmacogenomics has had a good development in most of medical specialties, nevertheless in psychiatry has been particularly successful. Accordingly, it has been extremely useful in psychiatric patients considering how ...
Editorial: Improving cancer chemotherapy through pharmacogenomics: A research topic
(Frontiers Research Foundation, 2015)
Pharmacogenomics in Latin America: Challenges and Opportunities
(Nova Science Publishers, 2017)
Pharmacogenomics of antiretroviral therapy in Latin America
(Nova Science, 2017)
AIDS is caused by infection with human immunodeficiency virus (HIV), which when untreated produces a critical decline in CD4+ T cells, triggering a progressive dysfunction of the immune system and the development of ...
Perception of the usefulness of drug/gene pairs and barriers for pharmacogenomics in latin America
(Bentham Science Publishers B.V., 2014)
Pharmacogenetics and Pharmacogenomics areas are currently emerging fields focused to manage pharmacotherapy that may prevent undertreatment while avoiding associated drug toxicity in patients. Large international differences ...